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Abstract
Objectives: We aim to describe rates and risk factors of Hepatitis C Virus (HCV)
diagnoses, follow-up HCV testing and HCV seroconversion from 2004–2011 in a
cohort of HIV-positive persons in Spain.
Methods: CoRIS is a multicentre, open and prospective cohort recruiting adult HIV-
positive patients naı¨ve to antiretroviral therapy. We analysed patients with at least
one negative and one follow-up HCV serology. Incidence Rates (IR) were
calculated and multivariate Poisson regression was used to estimate adjusted
Rates Ratios (aIRR).
Results: Of 2112 subjects, 53 HCV diagnoses were observed, IR50.93/100py
(95%CI: 0.7–1.2). IR increased from 0.88 in 2004–05 to 1.36 in 2010–11
(aIRR51.55; 95%CI: 0.37–6.55). In men who have sex with men (MSM) from 0.76
to 1.10 (aIRR51.45; 95%CI: 0.31–6.82); in heterosexual (HTX) subjects from 1.19
to 1.28 (aIRR51.08; 95%CI: 0.11–10.24). HCV seroconversion rates decreased
from 1.77 to 0.65 (aIRR50.37; 95%CI: 0.12–1.11); in MSM from 1.06 to 0.49
(aIRR50.46; 95%CI: 0.09–2.31); in HTX from 2.55 to 0.59 (aIRR50.23; 95%CI:
0.06–0.98). HCV infection risk was higher for injecting drug users (IDU) compared
to HTX (aIRR59.63;95%CI: 2.9–32.2); among MSM, for subjects aged 40–50
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compared to 30 or less (IRR53.21; 95%CI: 1.7–6.2); and among HTX, for female
sex (aIRR52.35; 95%CI: 1.03–5.34) and ,200 CD4-count (aIRR52.39; 95%CI:
0.83–6.89).
Conclusion: We report increases in HCV diagnoses rates which seem secondary
to intensification of HCV follow-up testing but not to rises in HCV infection rates.
HCV IR is higher in IDU. In MSM, HCV IR increases with age. Among HTX, HCV IR
is higher in women and in subjects with impaired immunological situation.
Introduction
The epidemiology of hepatitis C virus (HCV) infection in persons living with
human immunodeficiency virus (HIV) in Western countries has changed
profoundly in the last 15 years [1–12]. Outbreaks of acute HCV infection have
been reported in HIV-positive men who have sex with men (MSM) from the mid-
2000s onwards in large cities in Europe [3–7, 9, 13] and the United States (US) [1]
and decreases in the numbers of injecting drug users (IDU) in industrialized
countries have led to decreases in HCV serial prevalence [14–16].
The impact of these HCV outbreaks on the global epidemiology of HCV
infection, particularly among HIV-positive patients, is yet to be described. In spite
of the relevance of HCV co-infection [17], surveillance of HCV is not sufficiently
developed in most European countries. Several European cohort studies have
described increasing rates of HCV diagnoses as well as of HCV seroconversions in
MSM since the mid-eighties to current date, but more markedly from 2002
onwards [2, 8, 10–11]. The Multicentre AIDS Cohort Study (MACS) has reported
the on-going HCV epidemic in HIV-positive MSM in the US from 1984 to 2011
but describes no actual increases of HCV infection over time [12].
Early diagnosis of HCV infection is the first step to access treatment, HCV
eradication and decreased on-going HCV transmission. However, though HCV
testing is recommended to all HIV-positive persons, there are currently no
guidelines on how often should HCV testing be repeated in HIV-positive patients
in the absence of clinical symptoms.
The objective of this work is to describe the rates and risk factors of HCV
diagnoses, follow-up HCV testing and HCV seroconversion from 2004 to 2011, in
a multicentre cohort of HIV-positive persons in Spain. We show the results
globally, for MSM and for people infected through heterosexual transmission
(HTX).
Methods
CoRIS (Spanish acronym for the AIDS Research Network Cohort) is an open,
prospective, multicentre cohort of adult (age 18 or older) patients with confirmed
part of the Plan Nacional R+D+ I and cofinanced
by ISCIII-Subdireccio´n General de Evaluacio´n and
the European Regional Development Fund
(ERDF). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
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HIV infection. It includes patients who began follow-up in any of the
participating sites after January 2004 while nai¨ve to antiretroviral treatment
(cART).
Ethics approval was obtained from all hospitals Ethics’ Committees (see Annex
for all hospitals participanting) and every patient provides a written informed
consent to participate in the cohort.
A complete description of the cohort has been published elsewhere [18].
Currently, 31 groups from 28 public health-care centres within 13 of Spain’s 17
Autonomous Regions participate in the cohort. Patients’ follow-up and frequency
of HCV testing are established by the physician in charge as there are no standard
recommendations for follow-up HCV testing in HIV-positive persons in Spain.
HIV-positive subjects were recruited from 2004 onwards up to the 31st October
2011– administrative censoring date. Eligibility criteria for these analyses required
having a documented negative HCV serology before or upon cohort recruitment
and at least one follow-up HCV test performed. Since eligibility for a follow-up
HCV test also depends on the length of clinical follow-up and the number of
visits, we further excluded patients with clinical follow-up periods under 2 years.
Definition of study outcomes
HCV diagnosis was defined based on positive HCV antibodies using a third
generation EIA (enzyme immunoassay). HCV diagnoses were verified by
consecutive confirmatory HCV-positive serologies, positive antigen determina-
tions and/or HCV viral load detection. HCV diagnoses that could not be
confirmed were also included, but sensitivity analyses excluding these cases were
also performed.
The date of HCV diagnosis was the date the first HCV test was positive.
Incidence rates of HCV diagnosis were calculated as the number of HCV
diagnoses per 100 person-years at risk (p-y), and patients were considered at risk
from the date of cohort entry to the date of their last negative HCV serology or the
date of HCV diagnosis.
The date of HCV infection (or date of HCV seroconversion) was estimated
using two different methods: a) the midpoint between the last negative and the
first positive HCV test for any time window (midpoint method) and b) a multiple
imputation technique (multiple imputation method). Rates of HCV infection were
calculated as the number of HCV seroconversions - excluding those estimated
before the date of patient’s inclusion in the cohort - per 100 person-years at risk
(p-y), and patients were considered at risk from the date of cohort entry to the
date of their last negative HCV serology or the date of HCV infection.
Rate of follow-up HCV tests were calculated as the number of persons with
follow-up HCV test in each period, per 100 person-years at risk of HCV diagnosis.
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Statistical analyses
Logistic regression models were fitted to evaluate sociodemographic character-
istics associated with a follow-up HCV test (gender, age at cohort entry,
educational level, country of origin, and transmission category -in mutually
excluding categories and prioritizing those with a higher risk of transmission-).
The multiple imputation technique was performed as follows: for each
diagnosis, the HCV seroconversion date (estimated date of infection) was
imputed by extracting a random date from a uniform distribution between the
last negative and the first positive HCV test, assuming that seroconversion was
equally probable at any given moment during that time window. This process was
replicated 20 times for each subject and a separate database was generated for each
replica. The final estimates were the result of combining individual estimates from
each replica using the procedure described by Rubin, which accounts for the
observed variability between estimations in the estimation of the global variance
[19].
Multivariate Poisson regression models were fitted to evaluate a priori
established sociodemographic risk factors for HCV incidence and CD4 cell count,
HIV Viral Load and cART, as time-changing variables.
To analyse trends in HCV incidence, Poisson regression models were used,
evaluating the presence of confounding variables for the association between
calendar period and HCV incidence. We obtained crude (IRR) and adjusted
(aIRR) incidence rate ratios, and their confidence intervals at 95% (95%CI).
We performed various simulations to evaluate the potential source of selection
bias derived from the exclusion of subjects who had not been tested for HCV
infection during follow-up assuming they had a different risk of HCV infection.
We assumed all subjects with a minimum of two years of follow-up had been
tested for HCV infection on the date of their last clinic visit and calculated the
number of simulated HCV infections for each calendar year under two different
scenarios assuming high and arbitrary HCV incidence rates; (1) a constant HCV
rate of 1.5 per 100 p-y, and (2) an increasing HCV rate overtime starting at 1.5 per
100 p-y in years 2004.05 mounting to 2.00 per 100 p-y in 2010–11. We aggregated
these numbers to the main analyses and obtained HCV time trends under these
simulated scenarios.
Finally, we conducted sensitivity analyses excluding the information of all HCV
serologies performed before cohort entry; that is, limiting analyses to subjects with
at least 2 HCV tests from cohort recruitment onwards.
Robust methods were used to estimate confidence intervals assuming a
correlation between subjects recruited at each site, and independence between
subjects recruited at different sites [20]. Analyses were conducted using Stata
(V.11, Stata Corporation, College Station, Texas, USA).
Incidence HCV in Cohort of HIV-Positive
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Results
Out of 7977 patients, baseline HCV serology was available for 7552 (Fig. 1). At
cohort recruitment, 1227 had a positive HCV serology; prevalent cases were older
and mainly IDU or ex-IDU (65%). Of the remaining 6425 patients with negative
baseline HCV serology, 4124 had at least one follow-up HCV test or more than
two years of follow-up (Fig. 1). In all, 2122 patients had at least one HCV test
repeated over time. Median time between HCV serologies was 1.34 years (IQR:
0.43–2.49) and median number of serologies per patient was 2 (IQR: 2–3).
Follow-up HCV testing was commoner in MSM, people under 50 years of age and
non-Spanish origin (Table 1). Further, the rate of follow-up tests increased over
time, reaching up to 85 follow-up HCV test per 100 person-years in the period
2010–2011; 89 per 100 p-y for MSM and 78 per 100 p-y for the heterosexually
infected (Table 2 and Fig. 2A, 2B, 2C). The percentage of positive HCV diagnoses
among the tested individuals dropped slightly over this period (2.6% in 2004–05
to 1.6% in 2010–11).
The majority of these 2122 persons were men (85%), infected through sexual
transmission (67% MSM and 29.3% HTX), and of Spanish origin (67%). Overall,
35% were under 30 and 25% over 50, with ages between 18 and 77 (Table 1).
Median CD4 count at recruitment was 399 (IQR: 224–592), median viral load was
4.6 log (IQR: 4.06–5.15) and 76% started cART during follow-up.
These 2122 individuals added up to 5689 p-y in whom 53 HCV diagnoses were
observed. In 48 cases, diagnosis could be confirmed and in five no further
serologic determinations had been performed. HCV diagnosis rate was IR50.93
(95%CI: 0.71–1.22) (Table 2). Global HCV diagnosis rates increased from 0.88 in
2004–05 to 1.36 in 2010–11 (IRR 1.55; 95%CI: 0.37–6.55) (Table 2, Fig. 2A).
Fig. 1. Patients flow-chart.
doi:10.1371/journal.pone.0116226.g001
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Among MSM, rates of HCV diagnosis increased from 0.76 to 1.10 per 100 p-y
(IRR 1.45; 95%CI: 0.31–6.82) (Table 2, Fig. 2B) and in HTX from 1.19 to 1.28 per
100 p-y (IRR 1.08; 95%CI: 0.11–10.24) (Table 2, Fig. 2C).
Using the multiple imputation method, infection rate was 0.83 (95%CI: 0.61–
1.13) after excluding the one individual with all imputed seroconversion dates
before cohort entry. HCV infection rate decreased from 1.77 to 0.65 per 100 p-y
(IRR50.37; 95%CI: 0.12–1.11) (Table 2, Fig. 2A). Among MSM it decreased from
1.06 to 0.49 per 100 p-y (IRR 0.46; 95%CI: 0.09–2.31) (Table 2, Fig. 2B). In HTX
it decreased from 2.55 to 0.59 per 100 p-y (IRR 0.23; 95%CI: 0.06–0.98) (Table 2,
Fig. 2C). Using the midpoint method, infection rate was 0.82 per 100 p-y (95%CI:
0.61–1.09) -seven patients were excluded because their seroconversion date was
before cohort entry-. Time trends of HCV infection rate using this method are
Table 1. Sociodemographic characteristics of 4124 patients with follow-up HCVtest or more than two years of follow-up: prevalence of repeated HCV tests
and multivariable logistic regression for the odds ratio (OR) of having a subsequent HCV serology.
Patients with follow-up HCV test or more than two years of follow-
up (n54,124) Adjusted OR (95% CI)
n %
Patients with follow-up
HCV serology
(n52,122)
Patients without
follow-up HCV
serology (n52,002)
n % n %
SEX
Male 3356 81.4 1797 53.5 1559 46.5 1
Female 768 18.6 325 42.3 443 57.7 0.96 (0.78–1.17)
TRANSMISSION CATEGORY
Heterosexuals 1471 35.7 621 42.2 850 57.8 1
Injecting drug users 63 1.5 22 34.9 41 65.1 0.74 (0.43–1.26)
Homo/bisexual men 2461 59.7 1422 57.8 1039 42.2 1.79 (1.50–2.13)
Other/Unknown/Not available 129 3.1 57 44.2 72 55.8 1.04 (0.72–1.51)
AGE AT ENTRY
,530 years 1423 34.5 752 52.8 671 47.2 1.29 (1.02–1.65)
31–40 years 1581 38.3 843 53.3 738 46.7 1.36 (1.07–1.72)
41–50 years 745 18.1 370 49.7 375 50.3 1.27 (0.98–1.64)
.50 years 375 9.1 157 41.9 218 58.1 1
EDUCATION LEVEL
Low 1301 31.5 627 48.2 674 51.8 1
Medium 1419 34.4 749 52.8 670 47.2 1.00 (0.85–1.17)
High 942 22.8 533 56.6 409 43.4 1.10 (0.92–1.31)
Not available 462 11.2 213 46.1 249 53.9 0.89 (0.72–1.10)
COUNTRY OF ORIGIN
Spain 2794 67.7 1416 50.7 1378 49.3 1
Other 1317 31.9 694 52.7 623 47.3 1.17 (1.02–1.34)
Not available 13 .3 12 1 –
TOTAL 4124 100.0 2122 51.5 2002 48.5
doi:10.1371/journal.pone.0116226.t001
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showed in Table 2 and Fig. 2. Only unadjusted results are shown, as they were not
confounded by any of the variables studied.
Factors independently associated with higher HCV infection were: being an
IDU (aIRR 9.63; 95%CI: 2.88–32.19) and, though not reaching statistical
significance, age 41–50 (aIRR 1.66; 95%CI: 0.85–3.24) and CD4 cell count below
200 cells/mm3 (aIRR 1.93; 95%CI: 0.90–4.15) (Table 3). In analyses restricted to
MSM, the only factor associated with a higher HCV infection was age 41–50 (IRR
3.21; 95%CI: 1.66–6.23). Among HTX, two factors showed independent
association with higher HCV infection rate: female sex (aIRR 2.35; 95%CI: 1.03–
5.34) and CD4 cell count below 200 cells/mm3 (aIRR 2.39; 95%CI: 0.83–6.89).
The analyses of the associated risk factors yielded similar results using the two
methods to estimate HCV seroconversion, for the cohort as a whole and for the
two transmission categories analysed separately (Table 4 in S1 File).
Results from simulation and sensitivity analyses
The simulation analysis assuming a constant HCV infection rate at 1.5 per 100 p-y
throughout the study period among patients without serological follow-up, still
showed a decrease in global infections rates. Assuming an increasing trend in
HCV infection, from 1.5 in 2004/05 to 2.0 per 100 p-y in 2010/11, did not led to
increases in HCV global infections rates, either (Tables 5a–5b in S2 File).
Excluding the HCV serologies performed before cohort entry restricted the
sample to 1490 patients and 4003 p-y of serological follow-up. Sensitivity analyses
showed very similar results for the incidence rate and risk factors, as well as for the
time-trend analyses, although some were underpowered (Tables 6–7 and Figure 3
in S3 File). Excluding non-confirmed HCV diagnoses did not change findings
either (Tables 8–9 and Figure 4 in S4 File).
Discussion
The HCV infection rate observed in our cohort is 0.82 per 100 p-y globally, 9.4 per
100 p-y in IDU, 0.6 per 100 p-y in MSM and heterosexually infected men, and 1.4
per 100 p-y in heterosexually infected women. We report increases in the rates of
HCV diagnoses in the last years which seem secondary to intensification of HCV
follow-up testing but not to rises in HCV infection rates in a cohort of HIV-
positive patients between 2004 and 2011 in Spain.
Injecting drug use remains the strongest risk factor for HCV infection rates,
though the number of IDUs is now very low in the cohort. MSM aged 41–50,
female heterosexuals and heterosexuals with CD4 cell count below 200 cells/mm3
had increased HCV infection rates.
HCV infection rates are, similar to those reported by earlier works conducted in
HIV positive individuals [2, 8, 12, 21, 22]. Eurosida reported global IR of 0.79 per
100 p-y during 2002–2010 [2]. In HIV-positive MSM, Van de Laart et al. reported
IR of 0.87 per 100 p-y during 2000–2003 [8], Taylor et al. IR50.51 per 100 p-y
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during 1996–2008 [22], Gamage et al. IR50.6 per 100 p-y during 2002–2010 [21]
and Witt et al. reported IR50.52 per 100 p-y during 2005–2011 [12].
The risk factors associated with HCV infection identified in these analysis are
comparable to previous studies; HCV infection is far higher in IDU
[8, 12, 21, 22, 23, 24] and, within the MSM, incidence increases with age [21]
although it stabilizes after age 50. HCV infection rates were similar between MSM
and men who only reported sex with women. Information bias due to under
disclosure of past injecting drug use cannot be ruled out.
We have observed that the HCV infection rate in subjects with CD4 cell counts
below 200 cells/mm3 is twice higher that of people with better immunological
situation, although results did not reach statistical significance. A recently
published study from the MACS describes that, in individuals with ,500 CD4
cells/mm3, HCV incidence was inversely associated with CD4 count [12], but
previous publications did not report these findings [11, 22]. We need to take into
Fig. 2. Time trends of rates of HCV diagnoses, HCV infections and of follow-up HCV tests, 2004–2011.
doi:10.1371/journal.pone.0116226.g002
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account that the statistical power of this result is limited, as the person-time spent
with CD4 cell counts below 200 cells/mm3 is short, and the rate of follow-up HCV
test was higher in subjects with ,200CD4 (RR51.3; 95%CI: 1.2–1.4).
Table 3. Rates and associated risk factors of HCV infection.
ALL subjects (n52,115)
Infections Person-years IR IRR (CI 95%) aIRR (CI 95%)
SEX
Male 33 4694.28 0.70 1 1
Female 13 941.43 1.38 1.96 (1.03–3.76) 1.58 (0.78–3.20)
TRANSMISSION CATEGORY
Heterosexuals 19 1846.42 1.03 1 1
Injecting drug users 5 53.31 9.38 9.11 (2.86–29.08) 9.63 (2.88–32.19)
Homo/bisexual men 21 3592.28 0.58 0.57 (0.24–1.36) 0.81 (0.29–2.27)
Other/Unknown 1 143.70 0.70 0.68 (0.10–4.79) 0.77 (0.11–5.50)
AGE AT ENTRY
,530 years 11 1866.73 0.59 1 1
31–40 years 19 2350.63 0.81 1.37 (0.57–3.30) 1.38 (0.57–3.30)
41–50 years 12 960.44 1.25 2.12 (1.15–3.90) 1.66 (0.85–3.24)
.50 years 4 457.91 0.87 1.48 (0.68–3.24) 1.29 (0.53–3.14)
CD4+ T-Cell Count
,200 cells/mm3 8 455.76 1.76 2.36 (1.17–4.75) 1.93 (0.90–4.15)
.5200 cells/mm3 38 5100.96 0.74 1 1
Not available 0 79.00 0.00
TOTAL 46 5635.72 0.82
Men who have sex with men (n51,416)
Infections Person-years IR IRR (CI 95%) aIRR (CI 95%)
AGE AT ENTRY
,530 years 5 1314.77 0.38 1 1
31–40 years 9 1562.66 0.58 1.51 (0.44–5.22) 1.51 (0.44–5.22)
41–50 years 6 490.79 1.22 3.21 (1.66–6.23) 3.21 (1.66–6.23)
.50 years 1 224.06 0.45 1.17 (0.24–5.67) 1.17 (0.24–5.67)
TOTAL 21 3592.28 0.58
Heterosexually acquired cases (n5620)
Infections Person-years IR IRR (CI 95%) aIRR (CI 95%)
SEX
Male 6 943.48 0.64 1 1
Female 13 902.95 1.44 2.26 (1.01–5.05) 2.35 (1.03–5.34)
CD4+ T-Cell Count
,200 cells/mm3 5 247.88 2.02 2.26 (0.78–6.53) 2.39 (0.83–6.89)
.5200 cells/mm3 14 1569.37 0.89 1 1
Not available 0 29.17 0.00 –- –-
TOTAL 19 1846.42 1.03
*The table shows all the variables included in the final multivariables models.
doi:10.1371/journal.pone.0116226.t003
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Follow-up HCV testing was more common in MSM, people under 50 years of
age and non-Spanish origin. It seems that qualitative and quantitative changes
regarding HCV testing have taken place in Spain in the last years. As a
consequence of the alert raised by the outbreaks of HCV infection in MSM, it
seems physicians are testing this group more frequently, increasing the number of
positive diagnoses as well, contributing to the denominator, and thus yielding
lower seroconversion rates. Further, selection bias due to more frequent and
selective HCV testing to a subset of HTX in whom a higher risk of infection is
perceived may also have taken place, particularly in the first period before HCV
testing become more widespread. This could be the case of the female sexual
partners of HCV-positive IDU. Heterosexual women had an HCV infection rate
twice higher than heterosexual men, similar to the PRIMO cohort and consistent
with unprotected sexual intercourse with male IDU [25]. Unfortunately, the
characteristics of the sexual partner/s of cohort members are not collected in
CoRIS. The decreasing trend of HCV infection in CoRIS is concordant with the
decrease in serial prevalence of HCV infection biomarkers reported by the Spanish
national biosurveillance network [26], as well as with the serial HCV prevalence
reported in CoRIS [14, 15].
Our time-trends results need to be placed in context of works which have found
an increasing HCV incidence in European countries in recent years [2], some of
them in MSM [8, 10, 11]. Eurosida reported an IR ranging from 0.47 to 2.34 per
100 p-y in the period 2002–2010 [2]. In HIV-positive MSM, Van de Laart et al.
reported an IR varying from 0.08 to 0.87 per 100 p-y in 1984–2003 [8], the Swiss
HIV Cohort an IR from 0.23 to 4.09 per 100 p-y in 1998–2011 [11], and in
CASCADE Collaboration IR ranged depending on the method used from 1.6 and
3.0 in 2005 to 2.34 and 5.11 per 100 p-y in 2007 [10]. In HTX, the Swiss HIV
Cohort reported a stabilized IR of less than 0.5 per 100 p-y [11].
For all groups and for MSM, we observe an increase of 50% in HCV diagnoses
rates that did not reach statistical significance; the decrease in HCV infections was
not significant either. This indicates that more cases are being diagnosed in recent
years, but that does not mean more infections are necessarily occurring. In HTX,
where the decrease in HCV seroconversions reaches statistical significance, the
increased follow-up HCV testing does not lead to changes in the diagnosis rates.
For time-trends analysis we considered multiple imputation as the most
appropriate method because the midpoint method underestimates the rates in the
two extremes of the timeframe.
As a limitation, we acknowledge that HCV testing in our cohort was performed
according to clinical criteria, rather than following a pre-specified screening
scheme, so we cannot rule out that those with available follow-up serologies are
those in which a higher probability of HCV infection was suspected; thus we could
have overestimated the rates of HCV diagnoses and of HCV infection in our
cohort. We think this is unlikely to having serious biased our results since the rate
of patients that undergo serological follow-up has increased more than two-fold
throughout the study period, to a similar degree in all transmission categories (34
to 86 per 100 p-y from 2004–05 to 2010–11), so it is possible that the non-
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significant increase we observe in HCV incidence is explained by an extension of
serological follow-up to low-risk subjects.
Though CoRIS is not population-based, subjects included in the cohort show
similar characteristics to those reported by Spanish national surveillance [27].
Therefore, our results can be extrapolated to the HIV-infected population in
Spain. On the other hand, excluding patients’ serological information previous to
cohort recruitment did not affect our estimates.
In conclusion, the increases in the rates of HCV diagnoses seem secondary to
intensification of HCV follow-up testing, which is unveiling previously
undiagnosed subjects, and not necessarily to rises in HCV infection. Repeating
HCV tests to all HIV-positive persons under follow-up has yielded an increase in
the number of cases, which is relevant both for clinical and public health
purposes. Further follow-up of this cohort under similar HCV testing practices
will provide additional evidence on the evolution of the rates of both HCV
diagnosis and HCV infection in order to issue recommendations of HCV testing
strategies in the HIV-positive population.
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